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Host genotype and time dependent 
antigen presentation of viral 
peptides: predictions from theory
R. Charlotte Eccleston1,2, Peter V. Coveney  1,2 & Neil Dalchau  3
The rate of progression of HIV infected individuals to AIDS is known to vary with the genotype of 
the host, and is linked to their allele of human leukocyte antigen (HLA) proteins, which present 
protein degradation products at the cell surface to circulating T-cells. HLA alleles are associated with 
Gag-specific T-cell responses that are protective against progression of the disease. While Pol is the 
most conserved HIV sequence, its association with immune control is not as strong. To gain a more 
thorough quantitative understanding of the factors that contribute to immunodominance, we have 
constructed a model of the recognition of HIV infection by the MHC class I pathway. Our model predicts 
surface presentation of HIV peptides over time, demonstrates the importance of viral protein kinetics, 
and provides evidence of the importance of Gag peptides in the long-term control of HIV infection. 
Furthermore, short-term dynamics are also predicted, with simulation of virion-derived peptides 
suggesting that efficient processing of Gag can lead to a 50% probability of presentation within 3 hours 
post-infection, as observed experimentally. In conjunction with epitope prediction algorithms, this 
modelling approach could be used to refine experimental targets for potential T-cell vaccines, both for 
HIV and other viruses.
The human immunodeficiency virus (HIV) is a fast mutating lentivirus that infects and eventually depletes T 
helper (Th) cells which are integral to adaptive immunity in vertebrates. As Th cell numbers decline, the infected 
individual becomes more susceptible to opportunistic infections and tumours. Therefore, HIV-infected indi-
viduals usually progress to acquired immunodeficiency syndrome (AIDS) within 10 years. However, 10–15% 
of people progress rapidly within three years of infection, whereas 5–10% remain asymptomatic for over 10 
years1. People who control HIV for many years are known as long term non-progressors (LTNPs). Long-term 
non-progression is not linked to viral defects2, but is due to the response of the infected individual’s immune sys-
tem. For example, an individual experiencing fast progression to AIDS, can transmit HIV to another individual 
who then becomes an elite controller (EC)3. Elite controllers comprise less than 1% of LTNPs, and have undetect-
able viral loads. More generally, understanding the factors that influence HIV progression rates and lead to long 
term control will aid in the design of vaccines, immunotherapy and personalised treatments.
Differing rates of progression in HIV-infected individuals are known to be linked to class I proteins of the 
Major Histocompatibility Complex (MHCI), which in humans are the human leukocyte antigen (HLA) pro-
teins4,5. MHCI molecules present peptides arising from intracellular protein turnover at the surface of nucleated 
cells, allowing cytotoxic T-lymphocytes (CTL) the opportunity to detect intracellular pathogens such as viruses 
and bacteria, or cancerous mutations in self-proteins. Immunoproteasomes cleave peptides of lengths between 8 
and 15 amino acids from proteins. Peptides are then transported into the endoplasmic reticulum (ER) via trans-
porter associated with antigen processing (TAP) molecules, where they can bind to MHCI. Complexes formed 
may then be transported from the ER to the cell surface. If the peptide-MHCI complex has high stability (low 
off-rate), then the peptide will be displayed at the cell surface for a longer duration, serving to enhance the immu-
nogenicity of the peptide6.
Several HLA alleles such as B*58, B*57, B*27 and B*44 have been found to be over-represented among LTNPs 
and ECs, and they are associated with Gag-specific CTL responses7–11. Many of these Gag-specific peptides orig-
inate from highly conserved regions of the Gag protein sequence12 and so escape mutations will likely lead to 
diminished viral fitness. For example, the known T242N escape mutation in the HLA-B*57/B*58:01 restricted 
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Gag epitope TW10 (TSTLQEQIGW) leads to diminished viral replication capacity5, as does the A163G mutation 
of the similarly restricted Gag KF11 (KAFSPEVIPMF) epitope13,14. There is also an association among the subset 
of infected individuals who progress rapidly to AIDS and the expression of the alleles HLA-B*35 and -B*18. 
These fast-progressing alleles are associated with CTL responses against non-Gag epitopes, such as those from 
the Nef and Env proteins15. The Env and Nef proteins are both highly variable, with Env being the most variable 
sequence in the HIV genome7 and mutations in these epitopes are fitness neutral16. These observations would 
suggest that the strong association with Gag-specific T-cell responses and control of HIV progression is due to 
the Gag protein sequence being highly conserved in the HIV genome. However, Pol protein sequence is known 
to be the most conserved in the HIV genome7, but association between Pol-specific T-cell responses and immune 
control of HIV is not as convincing.
Another factor that might influence why Gag is so dominant in HIV control is peptide abundance. There are 
approximately 4900 copies of Gag protein per HIV virion17, and Gag is the most abundant HIV protein in the host 
cell cytoplasm during replication, with a Gag-Pol ratio in both the virion and during replication of 20:118. There 
is a correlation between the abundance of epitopes from Gag proteins p17 and p24 in the endoplasmic reticulum 
(ER) and CTL immunodominance, but MHCI affinity only moderately influences the CTL response19. Since 99% 
of peptides in the cytoplasm degrade before encountering MHCI molecules in the ER20, peptides cleaved from 
high abundance proteins will have a greater probability of cell-surface presentation. Intracellular protein abun-
dance is therefore an important factor when trying to predict CTL epitopes.
The development of a successful HIV T-cell vaccine would require the identification of dominant and 
sub-dominant T-cell epitopes originating from conserved regions of the HIV genome, to minimise the impact 
of escape mutations. T-cell epitopes can be discovered using high-throughput experimental methods, but such 
methods can only scan a limited number of proteins and MHCI alleles at a given time. Furthermore, such proce-
dures are expensive and it is infeasible at present to perform full scans of all potential T-cell epitopes for complex 
viruses such as HIV21. The construction of models that predict the cell surface presentation of viral or cancer-
ous peptides is therefore of paramount concern in biology and medicine. Towards the goal of predicting T-cell 
epitopes, there has been considerable work. Machine learning algorithms have been applied to large sets of exper-
imental data, with artificial neural networks and matrix-based models trained to make reliable predictions about 
which sequences are likely to be immunogenic22,23. The Immune Epitope Data Base (IEDB) MHCI processing tool 
takes a protein amino acid sequence as input and predicts which peptide sequences will be produced. For each 
peptide the tool provides predictions of proteasomal cleavage, TAP transport and MHCI binding24 and provides a 
measure of how likely it is for a specific peptide sequence to be presented on the cell surface by the chosen MHCI 
allele.
In this paper, we present a new predictive mechanistic model of cell surface peptide presentation following 
HIV infection. The model combines the peptide specific properties predicted by the IEDB MHCI processing tool 
and a mechanistic model of infection that includes intracellular peptide abundance and viral lifecycle kinetics, 
factors that have previously not been considered in a quantitative framework25. The resulting model is a large sys-
tem of ordinary differential equations (ODEs). The aim is to improve our understanding of the dominant factors 
within the intracellular peptide processing pathway and to be able to use such a model to accurately predict the 
timing and hierarchy of viral peptide presentation on the cell surface at different stages post infection of a cell. By 
combining viral protein kinetics with predictions of relative proteasomal cleavage rates we can model the dynam-
ics of peptide production in the cytoplasm, which subsequently impacts the concentration of these peptides in 
the ER, and thus the amount of peptide available for binding to MHCI. In the context of viruses such as HIV, 
early forming proteins such as Rev, Tat and Nef, are translated several hours before the remaining HIV proteins, 
including the important structural proteins Gag, Pol and Env. Using the model, we assess the impact of viral 
protein kinetics on peptide presentation. We also compare the importance of factors such as protein synthesis, 
proteasomal cleavage and peptide-MHCI affinity on the peptide abundance at the cell surface, thereby gaining a 
greater understanding of the intracellular antigen processing pathway.
Results
IEDB predictions cannot explain immunodominance of Gag epitopes. To determine the extent to 
which the association between Gag epitopes and HIV control may be predicted from static models of peptide pro-
cessing and MHCI binding, we used the MHCI processing tools from IEDB (see Methods). We used the HIV-1 
clade C proteome as input to the tool, which predicts the peptidome of an amino acid sequence, the probability 
of proteasomal cleavage, TAP affinity and the affinity (IC50) between the peptide and chosen MHCI allele (see 
Methods for further details). The tool combines these three measures into a ‘Total Score’, which is designed to 
be proportional to cell surface abundance of the peptide. Thus, the higher the score, the more immunodominant 
the peptide. We selected and compared the peptides within the top 1% Total Score for four alleles associated with 
long term control of HIV: HLA-B*58:01, B*57:01, B*27:05 and B*44:037–11, and four alleles associated with fast 
progression: HLA-B*18:01, B*35:03, B*07:02 and B*55:0115,26. Finally, we compared each HIV protein by taking 
the average Total Score of peptides from each protein (Fig. 1A,C), and recorded the total number of peptides from 
each protein that were predicted to be presented (Fig. 1B,D).
Due to the strong association with the presentation of Gag epitopes, we would expect that for the alleles asso-
ciated with long term non-progression, the highest Total Scores would come from Gag peptides and on average 
Gag peptides would have a higher Total Score. However, the average Gag Total Score was one of the lowest for 
the controlling alleles, with the highest average scores coming from Pol, Env, Nef and Vif in general (Fig. 1C). 
Similarly, for the controlling alleles HLA-B*58:01, B*44:03 and B*57:01, Pol and Env were the two proteins pre-
dicted to produce the largest number of binding peptides to the controlling alleles (Fig. 1D), and not Gag.
When comparing progressors to LTNPs, we found that the average Total Score for the peptides presented by 
the non-controlling alleles B*35:03 and B*55:01 was much lower for each protein than the controlling alleles 
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(Fig. 1A,B), which suggests that these alleles do not present immunogenic epitopes, and so are unable to control 
the spread of the virus. However, the non-controlling B*07:02 allele was predicted to bind a similar number of 
Pol, Env and Gag peptides. Furthermore, the B*18:01 allele was predicted to bind a similar number of peptides 
overall as the controlling alleles, and with a similar range of Total Scores. Focussing on Gag-derived peptides 
alone, we found that the highest average Total Score is associated with the controlling allele B*58:01, and the 
lowest average Total Score is associated with the non-controlling allele B*35:03. However, again we found no 
obvious distinction between the average Gag peptide Total Scores between the chosen set of controlling and 
non-controlling alleles that could explain their observed differences in rates of disease progression. In fact, from 
these predictions, we would expect Pol peptides to control HIV progression, as Pol is a highly conserved sequence 
and yields a large number of peptides with high Total Scores. In contrast, the Env sequence is highly variable27, 
so even though it also produces many peptides with high Total Scores, the higher probability of escape mutations 
reduces its immunogenicity.
Borghans et al.28 compared the predicted ranks of peptides from different HIV-1 proteins between a group of 
controlling alleles (HLA-B*27:05, -B*57:01 and -B*58:01) and a group of non-controlling alleles (HLA-B*35:03 
and -B*53:01). When comparing the ranks of the top 3 best binding Gag peptides they found the controlling 
group had a significantly higher preference for Gag than the non-controlling group. They also found that the 
non-controlling group had a preference for Nef peptides compared to the controlling group when analysing the 
top 3 best Nef-derived binders. Significant differences in the preferences for Vpu, p17, Vif and Ref peptides were 
Figure 1. The IEDB prediction tool suggests that Pol and Env produce the majority of peptides presented on 
HLA molecules. The IEDB MHCI processing tools were used to analyse the distribution of the top 1% of HIV-
1-derived peptides predicted to be presented on MHCI molecules. The predictions were made for controlling 
alleles, HLA-B*58:01, B*44:03, B*57:01 and B*27:05, and non-controlling alleles B*07:02, B*18:01, B*55:01 
and B*35:03. (A,C) The IEDB Total Score for each peptide is plotted according to which protein they originate 
from. The red crosses indicate the average total score of peptides from each protein. (B,D) The number of 
peptides in the top 1% is compared for each protein.
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also observed but it was concluded that the median ranks of these peptides were so high that the differences were 
most likely not physiologically important.
We carried out a similar analysis by comparing the median predicted Total Score of all peptides in the top 1 
% of each allele when grouping the alleles by their association with long-term control, and then asking whether 
the Total Scores are differ significantly, using the Wilcoxon rank-sum test (as used by Borghans et al.28; Fig. 2). 
A statistically significant difference was observed for all HIV proteins considered, suggesting that controlling 
alleles preferentially bind HIV peptides from Nef (p = 3.6 × 10−6), Gag (p = 2.4 × 10−6), Pol (p = 3.1 × 10−18), 
Env (p = 1.5 × 10−24), Vif (p = 1.2 × 10−5), Vpr (p = 0.0058) and Vpu (p = 1.0 × 10−4) in general compared to 
non-controlling alleles (Ref and Tat were not included due to the low numbers of peptides from these proteins in 
the top 1 %). This analysis suggests that controlling alleles are better suited in general to present peptides from the 
entire HIV genome although we could conclude that we would expect the two proteins with the lowest p-values, 
Pol and Env to be associated with control of HIV. However, as noted above, this IEDB-based analysis does not 
provide any explanation for the immunodominance of Gag epitopes.
One conflating factor in using the IEDB predictors to establish whether a given HLA allele is likely to control 
HIV infection is that they do not account for differential intracellular abundance and kinetics of the proteins from 
which the peptides are cleaved. Therefore, to determine whether the kinetics and abundance of HIV proteins can 
be determinants of HIV control, we must consider dynamic models of viral infection and MHCI presentation.
Construction of a combined model of HIV infection and peptide-MHCI presentation. To 
address the question of HLA-dependent control of HIV from a dynamical perspective, and simultaneously 
gain greater understanding of the mechanisms underlying antigen presentation, we constructed a combined 
model of HIV intracellular kinetics and MHCI peptide presentation (Fig. 3). Our model accounts for the impact 
viral protein dynamics have on peptide presentation, whilst using the predictive power of the IEDB processing 
tool to provide relative values for peptide specific parameters. We attempted to include as many of the known 
sequence-dependent steps of the intracellular antigen presentation pathway, to enable us to compare which are 
most influential, how presentation differs between early and late appearing proteins, and between high abundance 
and low abundance proteins. The model constructed enables us to produce time-dependent predictions of the 
cell surface peptidome associated with specific HLA alleles following HIV infection and viral genome integration, 
comparing these predictions between controlling and non-controlling alleles.
The model incorporates three existing ODE (ordinary differential equation) models of HIV-1 intracellular 
kinetics: Kim & Yin29, Reddy & Yin18 and Wang & LuHua30. HIV has been studied in detail and all three of 
these models are based on a wealth of experimental data that characterizes the rates of HIV mRNA transcrip-
tion, ratios of HIV protein translation and half-lives, protein cytoplasmic concentrations and interactions with 
host proteins, and the mechanisms and kinetics of viral replication and virion budding. The articles introducing 
each of the three models focussed on a different aspect of HIV intracellular kinetics. The combined model is a 
large system of coupled ODEs which uses experimentally determined reaction rates, or rates inferred from the 
IEDB processing tool, to describe the dynamic presentation of HIV-1 peptides following the infection of a cell 
by a HIV-1 virion. The model describes the steps of HIV-1 intracellular kinetics, including in the translation of 
the HIV-1 proteasome, beginning with the synthesis of full-length HIV-1 mRNA following the integration of 
an HIV-1 genome in to the host genome. The full-length mRNA encodes for the proteins Gag and GagPol and 
is spliced in the nucleus in to singly-spliced mRNA, which encodes for the proteins Env, Vif, Vpr and Vpu. The 
singly-spliced mRNA is spliced to form multiply-spliced mRNA which encodes for the regulatory proteins Rev 
Figure 2. Controlling alleles process and present HIV peptides more efficiently than non-controlling alleles. 
The IEDB processing tool Total Scores calculated in Fig. 1 were combined into sets of HIV peptides for 
controlling and non-controlling alleles. Their median (green crosses) were compared using a Wilcoxon rank-
sum test. A significantly higher median Total Score when binding to the controlling group was observed for all 
HIV proteins included in the analysis, suggesting controlling alleles preferentially bind HIV peptides in general 
compared to non-controlling alleles.
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and Tat. Only multiply-spliced mRNA can independently export to the cytoplasm, where Rev and Tat are trans-
lated and then re-enter the nucleus so Rev can bind to the larger viral mRNAs and allow for nuclear export, and 
so Tat can increase the rate of transcription of full-length mRNA. By combining the three models we are able to 
model the intracellular kinetics of the HIV-1 proteins Gag, Pol, Env, Rev, Tat and Vif, including budding of new 
virions. Inside each virion there are approximately 4900 copies of Gag and 700 copies of Vpr, a ratio of 7:117. The 
Pol protein is found at a ratio 1:20 compared to Gag31, with around 245 copies per virion. The copy numbers for 
the other proteins that comprise the HIV virion are as follows: Vif, 10130; Env, 28218; Nef, 15032; Vpu, unknown; 
Tat, none; Rev: none. We therefore set the synthesis rates of the proteins and degradation rates not included in 
either of the models, Vpr, Vpu and Nef, so that their numbers in the virions matched the measured values, where 
available, using experimentally measured half-lives (see Table S1 for parameter values).
The combined model of HIV kinetics enabled us to simulate the dynamics of all nine HIV-1 proteins following 
the infection of a single cell by a virion particle (Fig. 4A). We then combined this model with the peptide filtering 
model33, which describes MHCI peptide binding and presentation. In the peptide filtering model, a peptide is 
supplied to the ER where is it available for binding to MHCI or tapasin-MHCI complexes. The presence of tapasin 
increases the unbinding rate of the peptide from the MHCI molecule, and so acts as a filtering mechanism by 
which only those peptides with a high affinity for the MHC in question stay bound long enough to egress to the 
cell surface. Therefore, cell surface abundance of peptide-MHCI complexes ([MP]ics; here i denotes a specific pep-
tide sequence) is approximately inversely proportional to the square of its unbinding rate ui (see Supplementary 
Table S4). To combine the model of HIV intracellular kinetics and the model of peptide filtering we included the 
steps of peptide cleavage during protein degradation within the proteasome, peptide degradation in the cyto-
plasm, and peptide supply to the ER via TAP, according to
d P
dt
pc k g P d P
[ ]
[Prot ] [ ] [ ] (1)
i
i j j j i i P i
cyt
, cyt cyti C,= ⋅ − −
where Pi is the peptide of sequence i, and its cytoplasmic/ER concentration is given by [Pi]cyt and [Pi] respectively. 
The peptide Pi is cleaved from protein Protj with rate constant and ⋅pc ki j deg
Prot
,
j, which is the probability that the 
peptide will be produced via the degradation of one protein of type j. Peptide Pi can then be degraded in the cyto-
plasm with rate constant dPi C,  or transported to the ER with rate constant gi. The term g P[ ]i i cyt acts as the supply 
rate of peptide Pi to the ER and so connects the model of HIV protein kinetics with the model of peptide-MHCI 
binding (see Methods section for detailed description of model and parameter values). We use the IEDB peptide 
MHC-I processing tool (http://tools.iedb.org/processing/) to predict which peptide sequences will be produced 
by each HIV-1 protein, using the amino acid sequence of the HIV-1 clade C proteome as input to the tool. The 
processing tool provides predictions of the peptide-MHC affinity and the proteasomal cleavage probability that 
can be used to parameterise Equation 1.
Simulation of HIV-1 epitope presentation: Gag peptides dominate at the cell surface. Initially, 
we considered the HIV-1 replication kinetics with deterministic rate equations as the proteins are synthesised to 
high abundance following reverse transcription. In keeping with the existing models of HIV kinetics, the Gag 
Figure 3. Combined model of HIV-1 infection and cell surface peptide presentation on MHCI molecules. 
Diagrammatic representation of the combination of the separate models that comprise the combined model: the 
HIV kinetics models18,29,30, and the peptide filtering model33.
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protein had the highest cytoplasmic and virion abundance. Experimental evidence suggests that the Gag:Pol ratio 
in the virion of 20:1 is maintained in the cytoplasm31. Initially, we considered the presentation of an efficient pep-
tide for each HIV protein, to determine which will produce the most abundant peptides on the cell surface. The 
efficient peptide was defined as having a high affinity for MHCI encoded as a low unbinding rate (u = 1 × 10−5 
s−1), a high probability of proteasome cleavage ( = .pc 0 1i j, ), and a rate of supply into the ER ( = .g 0 08i  peptides 
s−1). In this way we are initially not considering any specific peptides but looking at peptide presentation as deter-
mined only by the differences in the kinetics of the originating protein.
The early synthesised regulatory proteins, Rev, Tat and Nef, are the first to appear in the cell cytoplasm at 
around 9 hours post infection, and are the first HIV proteins translated before the downregulation of MHC-I 
by Nef. Peptides derived from these regulatory proteins are frequently targets of CTL response, and so may be 
good targets for a HIV-1 vaccines34. Rev and Tat shuttle between the cytoplasm and the nucleus, in order to reg-
ulate HIV mRNA nuclear export, and viral genome translation respectively29. The model predicts that this rapid 
shuttling means that the Rev and Tat proteins accumulate slower in the cytoplasm that Nef, and even at steady 
state the cytoplasmic abundance of these two early proteins is much lower than that of all other HIV-1 proteins 
(Fig. 4A). As a consequence, out of the three early HIV proteins, the model predicts that only an optimal epitope 
deriving from the Nef protein will be presented significantly early, around 12 hours post-infection, whilst the 
optimal epitopes from Rev and Tat do not appear on the cell surface in substantial amounts until after the opti-
mal epitopes from the later proteins, Gag, Pol, Env, Vif, Vpr and Vpu, which appear at around 15–16 hours post 
infection (Fig. 4B). This suggests that any benefit that would be gained by targeting epitopes from the early HIV 
proteins before MHC-I downregulation would only be applicable in the case of Nef epitopes and not Rev or Tat.
As would be expected, the Gag peptide dominates cell surface abundance, with a Gag:Pol ratio of 18:1, a 
Gag:Vpr ratio of 23:1 and a Gag:Env ratio of 64:1. While there are very few published measurements of the cell 
surface abundance of HIV peptides, it has been determined that the ratio in the presentation of two HLA-A2 
restricted peptides, gag 77–85 (SLYNTVATL) and pol RT 476–484 (ILKEPVHGV), is around 30:135. The authors 
further suggest that this is consistent with the ratios of Gag and Pol in the virion and cytoplasm, around 20:1. 
Whilst we would expect the Gag epitope to be the most abundant on the cell surface due to the high Gag copy 
number, the ranking of the cell surface abundance for the epitopes deriving from the other proteins does not 
necessarily follow the ranking of their cytoplasmic abundances. The Vpr protein is the second most abundant in 
the cytoplasm, but the Pol peptide is the second most abundant on the cell surface. Similarly, the Env protein is 
the third most abundant in the cytoplasm, however, its epitope is only the sixth most abundant on the cell surface. 
This highlights how important the trade-off between protein synthesis and degradation is for peptide cell surface 
presentation: Vpr is a very stable protein36, and so whilst it is in high abundance in the cytoplasm, it degrades 
slowly, producing few peptides per unit time. A similar argument can be used to explain the discrepancies in 
the ranking of the Env protein and its epitope. Therefore, when trying to predict whether an epitope would be 
presented on the cell surface it is important to not only consider the abundance of the protein from which it orig-
inates but also the rate at which it degrades.
Differential sensitivity analysis of the combined model. To establish a more comprehensive insight 
into the dependency of the model on the underlying parameters, we performed a differential sensitivity analysis 
Figure 4. Example simulation of the combined model of HIV infection and peptide-MHCI presentation. (A) 
Simulated levels of HIV-1 proteins produced during replication (calculated deterministically). The complete 
model that produces all HIV-1 proteins is a combination of three existing models Kim & Yin29,52, Reddy & Yin18, 
and Wang & LuHua30. (B) Simulated cell surface abundance of efficient peptides derived from each protein, 




7Scientific REpoRts | 7: 14367  | DOI:10.1038/s41598-017-14415-8
on the cell surface abundance, [MPi]cs, of an epitope for seven of the nine HIV proteins separately (Fig. 5; see 
Methods for details). To enable comparison of several parameters of the model, we computed the normalised 
sensitivity coefficients, which approximate report the scaling of the model behaviour to the parameter of inter-
est37. In particular, a normalised sensitivity coefficient of 1 indicates a positive linear dependence on the parame-
ter, while a coefficient of −2 indicates an inversely quadratic dependence. Applied to the combined model, there 
was a mostly linear dependency upon protein synthesis fj for most proteins as time progressed (Fig. 5A). 
Presentation of Tat and Rev peptides had transiently nonlinear dependencies on their protein synthesis rates, 
which might have resulted from the effects of nuclear transport of these proteins. A more significant difference 
was for presentation of Gag peptides, which are associated with much higher protein synthesis rates than the 
other HIV proteins (Fig. 5A). Gag presentation showed a sublinear dependence on protein synthesis, which may 
be caused by the rapid accumulation of Gag epitopes resulting in being limited instead by ER translocation of 
cytoplasmic peptide. Interestingly, the dependence of [MPi]cs on protein degradation (kj) was sublinear as time 
progressed for each protein considered (Fig. 5B), meaning cell surface abundance is in general less sensitive to 
changes in the protein degradation rate than the synthesis rate. Finally, we observed an almost constant linear 
dependence on proteasomal cleavage (pc; Fig. 5C), but a sublinear dependence on TAP-mediated translocation 
(g ; Fig. 5D). It is possible that the low influence of TAP could be due to its co-evolved specificity with the 
proteasome38.
Figure 5. Sensitivity analysis of the combined model. We calculated the sensitivity of the cell surface 
presentation of optimal epitopes (as in Fig. 4) to seven of the model parameters: probability of protein 
translation fi (j denotes the protein), cytoplasmic degradation kj, proteasomal cleavage probability pc, supply 
rate to the ER g, peptide-MHCI unbinding rate u, peptide-MHCI binding rate b, and the peptide-MHC-tapasin 
binding rate cP. The sensitivities were calculated using the CVODES module of the SUNDIALs package63, then 
normalised, as described in the Methods section.
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Cell surface presentation is dominated by peptide processing initially, then gives way to peptide off-rate. With 
regards to the peptide-dependent parameters, there was a consistently linear dependence of peptide-MHCI cell 
surface abundance on proteasomal cleavage probability pc for each protein (Fig. 5C), whereas the dependence on 
the peptide ER supply rate g was sublinear (Fig. 5D), suggesting proteasomal cleavage is more important to an 
epitopes immunogenicity than the ER supply rate, and thus the epitopes affinity to TAP. The normalised sensitiv-
ity with respect to small increases in the value of the peptide-MHC unbinding rate u became more negative with 
time, and approached −1.5 by 72 hours post infection (Fig. 5E), and eventually plateaus at around −2 in equilib-
rium (data not shown). This near-quadratic dependency agrees with the relation ∝MP u[ ] 1/i ics
2 proposed 
previously33.
The normalised sensitivity with respect to the rates of peptide binding free MHCI, bP (Fig. 5F), and 
tapasin-bound MHCI, cP (Fig. 5G), were both sublinear, but small increases in bP result in a smaller increase in 
cell surface abundance than small increases in cP do. In the peptide filtering model33, c bP P> , and MT M[ ] [ ], 
and therefore the peptide binding rate to tapasin-bound MHCI is more important to overall cell surface peptide 
abundance. Overall, this sensitivity analysis suggests that if T-cell immunodominance hierarchies are established 
early following infection, then the steps of peptide processing, such as protein synthesis and proteasomal cleavage, 
as opposed to MHCI stability alone, could be more important than previously thought. As time progresses, how-
ever, the MHC stability becomes more important, as demonstrated by the increasing normalised sensitivity of 
MP[ ]i cs with respect to the peptide-MHCI unbinding rate ui.
Simulated HIV-1 peptide presentation by controlling and non-controlling HLA alleles. We per-
formed simulations of peptide-MHCI presentation of HIV-derived peptides for up to 72 hours post infection 
using the combined model, and compared four controlling alleles HLA-B*58:01, B*57:01, B*27:05 and B*44:037–
11 and four non-controlling alleles, HLA-B*18:01, B*35:03, B*07:02 and B*55:0115,26. We then analysed the twelve 
most abundant peptides presented on the cell surface at 16, 24 and 72 hours post infection, and determined which 
protein they originated from (Figs 6 and 7).
Most alleles transiently present Nef-derived peptides but become dominated by Gag-derived peptides. At 16 hours 
post-infection, the model predicts that all controlling and non-controlling alleles present a mixture of Nef (yellow 
bars) and Gag peptides (purple bars) (Figs 6A and 7A), with the exception of HLA-B*27:05, which also presents 
a single Vif peptide. Whereas, at later time-points, the Nef-derived peptides mostly become displaced, effectively 
limiting the impact of CTL responses mounted against these peptides. By 24 hours post-infection, the controlling 
alleles almost exclusively present Gag-derived peptides in the top 12, except for B*44:03, which presents 2 Pol and 
1 Vif peptide (Fig. 6B). The non-controlling alleles present slightly more of a mixture. B*07:02 and B*55:01 pres-
ent Gag and Vpr peptides, B*18:01 a mixture of Gag, Pol and Nef peptides, whilst B*35:03 presents Gag, Pol, Nef 
and Vpr peptides (Fig. 7B). By 72 hours post-infection, the controlling allele B*27:05 continues to present exclu-
sively Gag peptides in the top 12, while the number of Pol peptides presented by B*58:01, B*57:01 and B*44:03 
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Table 1. Equations describing intracellular kinetics of HIV transcripts and the Rev and Tat proteins. All 
equations and parameters are taken from Kim & Yin29.
www.nature.com/scientificreports/
9Scientific REpoRts | 7: 14367  | DOI:10.1038/s41598-017-14415-8
increases considerably (Fig. 6C). The non-controlling alleles continue to present more broadly across the HIV 
proteins (Fig. 7C). Of particular note is B*18:01, which presents mostly Pol peptides, and only 2 Gag in the top 12.
In summary, the distribution of peptides presented by controlling and non-controlling alleles is similar 
at 16 hours post-infection, however some distinctions arise at later time points. The top three most abundant 
Figure 6. Controlling alleles all demonstrate sustained Gag peptide presentation, and/or combined Gag and 
Pol peptide presentation at later times post infection. The combined model was used to predict the cell surface 
abundance of HIV-1 peptides in controlling alleles (B*58:01, B*57:01, B*44:03 and B*27:05) over time. The 
top 12 most abundant peptides at (A) 16, (B) 24 and (C) 72 hours post-infection are shown, with bar colours 
indicating the originating protein. All controlling alleles presented several Gag peptides by 16 hours, with 
the number of Gag peptides increasing by 24 hours post-infection. The presentation of Gag peptides at high 
abundance is sustained up to 72 hours post-infection.
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peptides at 72 hours post-infection presented by all the controlling alleles are exclusively Gag peptides, though 
this is also true of the non-controlling B*07:02 allele. However, B*55:01 presents 1 Vpr and 2 Gag in the top 
three at both 24 hours and 72 hours, whilst B*35:03, which presents exclusively Gag in the top 3 at 24 hours 
post-infection, also presents 1 Vpr and 2 Gag in the top 3 by 72 hours post-infection. While Vpr peptides are pres-
ent in the top 12 of three out of the four non-controlling alleles’ top 12 peptides (B*07:02, B*55:01 and B*35:03) 
by 72 hours post-infection, Vpr peptides were absent in the top 12 of all controlling alleles.
Figure 7. Non controlling alleles are either unable to sustain high levels of Gag peptide presentation, or present 
a combination of Gag and Vpr peptides at later times post infection. The combined model was used to predict 
the cell surface abundance of HIV-1 peptides non-controlling alleles (B*07:02, B*18:01, B*55:01 and B*35:03) 
over time. The top 12 most abundant peptides at (A) 16, (B) 24 and (C) 72 hours post-infection are shown, with 
bar colours indicating the originating protein.
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Non-controlling alleles present Vpr peptides in high average abundance. To provide a broader perspective of the 
appearance of peptides from specific proteins being presented, we analysed the average abundance of the peptides 
from each protein at 16, 24 and 72 hours post-infection (Supplementary Figures S1 and S2). At both 24 hours 
and 72 hours post-infection, B*58:01, B*57:01 and B*27:05 all presented Gag peptides with the highest average 
abundance, whilst for B*44:03, peptides from both Gag and Nef similarly high (Supplementary Figure S1B,C). 
Peptides from Nef, Pol and Env were also presented with high average abundance by B*58:01 and B*57:01 at 
24 hours post-infection. Notably, however, the average abundance of Vpr peptides presented by B*58:01, 
B*57:01 and B*44:03 was very low. Whereas, from 24 hours post-infection, Vpr peptides had the highest average 
abundance for the non-controlling alleles B*07:02 and B*55:01, and the third highest abundance for B*35:03 
(Supplementary Figure 2B,C). Therefore, when considering average peptide abundance and the distribution of 
the top 12 peptides, our simulations suggest that presenting a combination of Gag and Pol peptides provides bet-
ter protection against HIV disease progression than presenting a combination of Gag and Vpr peptides. Whilst 
the non-controlling allele HLA-B*18:01 does present Pol peptides alongside Gag peptides, it is the Pol peptides 
that dominate the top 3, suggesting that control of HIV progression requires that the Gag peptides dominate and 
are complemented by Pol peptide presentation. Furthermore, when considering the average peptide abundances, 
this allele presents Nef peptides with highest average abundance at all time points, whereas for all controlling 
alleles, Gag is in highest average abundance by 72 hours post-infection.
To assess how significant the differences predicted by our model are between the controlling and 
non-controlling alleles, we carried out a similar statistical analysis to before (Fig. 2). This time, we considered the 
top 1 % most abundant peptides from each allele and then grouped into controlling and non-controlling alleles. 
The median predicted cell surface abundance of peptides from each HIV protein was then analysed using a 
Wilcoxon rank-sum test. This was done for both 24 (Fig. 8a) and 72 (Fig. 8b) hours post infection, but not 
16 hours post infection due to the low number of peptides actually presented. We found that at both time points, 
controlling alleles presented peptides from Gag (24 hrs: p = 0.0432, 72 hrs: = . × −p 3 67 10 7) and Pol (24 hrs: 
p 0 0435= . , 72 hrs: = .p 0 0135) with statistically significant higher abundance, whilst non-controlling alleles 
were shown to present Vpr (24 hrs: = .p 0 0023, 72 hrs: = .p 0 0288) peptides with statistically significant higher 
abundance. It is interesting to note that at 24 hours post infection the most significant difference between the 
controlling and non-controlling alleles is in the abundance of Vpr peptides, whilst at 72 hours post infection Vpr 
has the lowest significance, with the highest being associated with the abundance of Gag epitopes. This corrobo-
rates our findings from considering the top 12 most abundant peptides from each allele, that non-controlling 
alleles have a preference for presenting Vpr peptides in high abundance, whereas controlling alleles preferentially 
present Pol and Gag. This also supports our assertion that whilst machine learning algorithms such as IEDB can 
predict differences in MHC binding affinities and proteasomal cleavage probabilities, using these tools alone it is 
not possible to predict differences in presentation as the protein dynamics are not taken in to account.
The dynamic model predicts the presentation of known HIV-1 epitopes by controlling alleles. When comparing 
the outputs of the combined dynamic model (Fig. 6D) with those resulting from the static predictions of the 
IEDB processing tool (Fig. 1), we found that the known epitopes rank higher in our combined model. The model 
predicted that the controlling alleles would all present known HIV Gag epitopes associated with HIV control by 
16 hours post-infection, and this presentation is sustained up to 72 hours post-infection (Fig. 6; Supplementary 
Table S2). For example, TW10 (TSTLQEQIAW) is a known p24 Gag epitope of B*58:01 and B*57:0139. The 
model predicts that TW10 is the second most abundant peptide presented by B*58:01, and alternates between 
the second and third most abundant peptide presented by B*57:01 (Fig. 6). However, the IEDB processing tool 
Figure 8. Controlling alleles prefer to present Gag and Pol peptides. The predicted abundance of the top 1% of 
HIV epitopes from different HIV proteins were grouped by controlling and non-controlling alleles. The median 
abundance of the top 1% predicted HIV peptides at (A) 24 hours and (B) 72 hours post infection was then 
compared using a Wilcoxon rank-sum test. At both time points, a significantly higher median abundance was 
observed for Gag and Pol peptides in the controller group, while a significantly higher median abundance was 
observed for Vpr peptides in the non-controlling group.
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predicts TW10 to have only the 28th highest Total Score for peptides binding to B*58:01 and only the 34th highest 
score for B*57:01.
The known Gag p24 KF11 (KAFSPEVIPMF) epitope of B*58:01 and B*57:0140 is predicted to be the 11th most 
abundant B*58:01 peptide at 16 hours post-infection, then increases to the 5th most abundant peptide, before slip-
ping down to 11th place by 72 hours post-infection (Fig. 6). Similarly, KF11 increases its rank among the peptides 
presented on B*57:01, reaching 6th position by 72 hours post-infection. However, KF11 is only ranked 23rd and 
16th by the IEDB Total Scores for B*58:01 and B*57:01 respectively.
Furthermore, the known B*58 and B*57 restricted Gag epitope ISPRTLNAW (IW9)28 is the 11th most abun-
dant B*58:01 peptide at 24 hours post-infection, but then displaced by Pol peptides at 72 hours post-infection. 
IW9 is consistently presented by B*57:01 at all three time points, being the 10th most abundant at 16 hours post 
infection, before increasing to 5th place and remaining there by 72 hours. IW9 has the 88th highest IEDB Total 
score for B*58:01 and the 54th highest total score for B*57:01.
Finally, the known B*27:05 restricted Gag epitope KK10 (KRWIILGLNK)41 is the 6th most abundant peptide at 
16 hours post-infection and the most abundant by 72 hours post-infection (Fig. 6, bottom row), however it is only 
ranked 29th by the IEDB Total Score. Also, known B*44:03 restricted epitope Gag AW11 (AEQATQDVKNW)42 
is the third most abundant peptide by 16 hours post-infection, but then reaches and remains the most abundant 
peptide from 24 hours onwards, however it has only the 13th highest predicted IEDB Total Score.
Peptide unbinding rates are more predictive of long-term cell surface presentation. Our simulations therefore 
clearly demonstrate that a peptides cell surface abundance may change significantly over time, and therefore 
become more or less immunogenic. For example, IW9 was only present in the top 12 most abundant peptides 
of B*58:01 transiently at 24 hours post infection but had been largely displaced by Pol peptides by 72 hours post 
infection. Our analysis suggests that this is due to the changing importance of peptide-specific parameters over 
time, as demonstrated by differential sensitivity analysis (Fig. 5). The Pol peptides (especially IAMESIVIW and 
KIAMESIVIW) that are predicted to be within the top 12 of both B*58:01 and B*57:01 at 72 hours post-infection 
both have very high predicted affinities for these alleles, and therefore have a low unbinding rate in our simula-
tions. As is demonstrated in Fig. 5E, the peptide-MHC unbinding rate becomes increasingly important over time, 
and by 72 hours post-infection, is more influential to cell surface abundance than any other parameter, including 
protein synthesis and degradation. Therefore, these Pol peptides begin to appear because their very low unbinding 
rate compensates for the lower abundance of the Pol protein in the cytoplasm compared to Gag. IAMESIVIW 
Pol is a known B57/B58 restricted HIV epitope, and is predicted by IEDB to have the highest and second highest 
total scores of any HIV peptide for B*58:01 and B*57:01 respectively. However, it does not appear in the top pre-
sented peptides until later on in infection. Therefore, as we have demonstrated, assigning a static immunogenicity 
score ignores the dynamics occurring during viral replication and peptide presentation, as well as the changing 
importance of peptide specific parameters, which when combined, creates a very complex system that cannot be 
efficiently described by a single metric.
Simulation of Virion-derived peptides reveals how Gag epitopes are likely to be presented 
within 3 hours of infection. The previous sections were concerned with monitoring cell surface 
peptide-MHCI presentation where the peptide originated from de novo protein synthesis following reverse tran-
scription of the viral genome into the host cell. Given the time lag induced by reverse transcription, protein syn-
thesis and then protein degradation, the first peptides do not arrive at the cell surface until approximately 10 hours 
post infection. However, the two protective Gag epitopes KF11 and KK10, restricted by HLA-B*57:01 and 
B*27:05 respectively, and the Pol KY9 B*27:05 restricted peptide have been detected on the surface of 
HIV-infected cells within 3 hours post-infection43, so could not have originated from de novo protein synthesis. 
Rather, these peptides presumably originated from the proteins that comprise the infecting virion(s). Therefore, 
we sought to determine whether our model could be used to simulate virion-derived peptide presentation. For 
peptides originating from de novo protein synthesis, the protein and peptide numbers become large (100) 
within our time window of interest, justifying the use of deterministic ODE simulations. However, virion-derived 
peptides will be in much lower abundance, preventing use of deterministic simulations for analysis. Therefore, we 
specified a stochastic version of our combined HIV kinetics model as a system of chemical reactions (see Methods 
for details).
Because stochastic simulations are more computationally expensive than deterministic simulations, we simu-
lated one efficient peptide for each virion protein (as opposed to multiple peptides per protein), similar to what 
was done in Fig. 4B. As before, the efficient peptide has a low unbinding rate ( = − −u s10 5 1), a high probability of 
proteasome cleavage ( = .p 0 1i j, ), and a fast rate of supply into the ER ( = .g 0 08i  peptides s
−1). In doing so, we 
could test how fast peptides can arrive at the surface of infected cells in a near-optimal scenario, establishing an 
approximate upper bound. The kinetics of the proteins contained in one virion over 9 hours post infection is 
shown in Fig. 9A. Each protein declines in abundance as it is degraded and converted into peptides. The resulting 
peptide presentation from a single infecting virion produced very low numbers for all peptides, with only the Gag 
peptide exceeding 1 copy on average (based on 300 independent simulations) within 9 hours. Therefore, the prob-
ability that a non-Gag peptide is presented from a single virion is small. However, if multiple virions enter a cell 
during infection, then this probability could increase and become immunologically relevant.
To investigate the impact of multiple virion infection and produce a more realistic quantification of the prob-
ability of infection, we used the well-known multiplicity of infection principle44, which quantifies the number of 
infecting virions using a Poisson distribution with mean 1, i.e. ∼N Poisson(1). For this calculation, we used 
conditional probability, which allows the total probability to be calculated in terms of the probability of presenta-
tion for a given number of virions (see Methods). Accordingly, we calculated the total probability of presentation 
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of a peptide from each HIV protein, over time, assuming Poisson-distributed virion numbers up to 5 (Fig. 9C,D). 
As N increases, the concentration of the proteins entering the cytoplasm increases, which means a larger number 
of peptides will be produced, increasing the probability that a given peptide would be presented. For all values of 
N, the Gag peptide is the most abundant on the cell surface. The total probability of Gag peptide presentation 
converges towards 0.63, equal to the probability that at least one virion infects the cell, i.e. P(N > 0). Crucially, we 
predict a greater than 50% chance that a Gag peptide will be presented by 3 hours post-infection, reconciling the 
observations in ref.43. Our model also predicted that an efficient Vpr peptide has a higher probability of presenta-
tion than an equivalently efficient Pol peptide. This may be because the Pol degradation rate we are using in this 
simulation is the same as the Gag-Pol polyprotein degradation rate (see Methods for more description). However, 
the Gag-Pol polyprotein is cleaved in to the enzymes integrase, reverse transcriptase and protease. The degrada-
tion of these smaller constituent proteins could be faster than that of the polyprotein, which will affect the timing 
and probability of presentation of the peptides cleaved from the Pol enzymes.
Discussion
The aim of this study was to predict the kinetics of the cell surface abundance of viral peptides throughout a 
viral replication cycle within a single infected cell. In doing so, we have made use of several bioinformatics tools 
that provide a static snapshot of the sequence-dependent processes that determine whether a peptide becomes a 
T-cell epitope. By embedding these tools in a dynamic model, we have been able to analyse how time-dependent 
factors, such as protein abundance, influence whether a peptide will be presented on the surface of virus-infected 
cells. The abundance of a peptide in the ER is dependent upon its cytoplasmic proteasomal cleavage probability 
and rate of transport in to the ER, here described via the peptide affinity with TAP. A higher ER abundance, along 
with a high affinity to the MHC allele in question will result in a high cell surface abundance, and thus a higher 
probability of T-cell response. To highlight the impact of time-dependent protein abundance and to provide a 
better conceptual understanding of the antigen presentation pathway and the important rate processes involved, 
we specifically applied these concepts to construct a mechanistic model of HIV-1 peptide presentation. However, 
the approach adopted here could in principle be applied to any virus, providing time-course measurements, or 
better still, a dynamic model, of intracellular protein abundance are available.
Figure 9. Stochastic simulation of virion-derived peptide presentation. The HIV virion model was simulated 
stochastically 300 times. (A) The mean HIV virion protein kinetics are shown for simulations of a single virion. 
(B) Mean cell surface abundance of optimal peptides from each of the 7 HIV proteins contained within a single 
virion. (C) Mean cell surface abundance of optimal peptides from 5 virions. (D) Using calculations of mean 
cell surface abundance, we approximated the probability of optimal peptide presentation using conditional 
probability, and by considering that the number of infecting virions is Poisson distributed with mean 1 (see 
Methods for details).
www.nature.com/scientificreports/
1 4Scientific REpoRts | 7: 14367  | DOI:10.1038/s41598-017-14415-8
We modelled both the presentation of peptides derived from the degradation of HIV-1 virion proteins, and 
those derived from the degradation of de novo synthesised HIV proteins during viral replication. Simulations of 
an efficient epitope for each HIV-1 protein predicted that Gag peptides would dominate at the cell surface. We 
used longer timescale (up to 72 hours post-infection) simulations of the model to compare peptide presentation 
by HLA alleles associated with control of HIV against HLA alleles associated with fast progression to AIDS. The 
machine learning algorithms used in the IEDB MHC-I prediction tools provide accurate predictions of epitopes 
when comparing peptide sequences from within the same protein. Therefore, in order to simulate the presenta-
tion of possible HIV peptides by different HLA alleles, we used the values of the peptide-MHCI affinity and 
proteasomal cleavage score, predicted by the IEDB MHC-I processing tool to infer relative parameter values 
for each peptide. A sensitivity analysis revealed that protein synthesis is more influential to cell surface peptide 
abundance than proteasomal degradation and the proteasomal cleavage probability pc is initially the most impor-
tant peptide-specific parameter to cell surface abundance, with the sensitivity constant with time. However, the 
importance of the peptide-MHCI unbinding rate u, increases with time, becoming the most important parameter 
by 36 hours post infection, suggesting sustained peptide-MHCI presentation is dependent upon the complex 
stability.
For peptides produced during de novo synthesis the model predicts that all alleles analysed herein will present 
a combination of Gag and Nef peptides at early times following infection, but eventually, Gag peptides can be 
displaced by highly stable peptides. For instance, alleles that are not associated with long-term control of HIV 
present Vpr peptides at high average abundance (B*07:02, B*55:01 and B*35:03) in combination with high aver-
age presentation of Gag, whereas alleles that are associated with long-term control present Vpr in very low average 
abundance, preferring to present a combination of Gag and Nef, Pol or Env in high abundance. As previously 
mentioned, the Pol protein is the most highly conserved sequence in HIV-1, and so stable binding to Pol-derived 
peptides would naturally confer protection. The time-dependent nature of cell surface abundance naturally raises 
the question of whether peptides presented earlier or later are better vaccine targets.
In a previous study that used peptide binding predictors to compare HIV epitopes across HLA alleles28, it was 
shown that the controlling alleles HLA-B*58:01,-B*57:01 and -B*27:05 have an intrinsic preference for p24 Gag 
peptides, whilst non-controlling alleles HLA-B*35:03 and -B*53:01 have a preference for Nef peptides. When 
considering the top three best-binding epitopes from each HIV-1 protein, this distinction was offered as an expla-
nation of why some HLA alleles are protective against HIV progression. In this study, where immunogenicity is 
explored using sequence binding preferences of HLA alleles in combination with protein kinetics and peptide 
processing steps, we predict that the controlling alleles considered by Borghans et al.28 present almost exclusively 
Gag peptides in high abundance at 24 hours post-infection, whereas B*35:03 has a more varied repertoire, includ-
ing peptides from Pol, Nef and Env (Fig. 6). Furthermore, we predict that the non-controller B*18:01 does not 
sustain high cell surface abundance of Gag-derived peptides, with Pol-derived peptides displacing them at later 
times, providing further support for the need for sustained and varied presentation of Gag peptides for control. 
Our simulations, however, do not provide any further support to the suggestion that the presentation of Nef pep-
tides is linked to fast HIV progression, but rather suggest that non-controlling alleles tend to present Vpr peptides 
in high abundance, and that this is less conducive to control.
Our analysis of the shorter timescale (up to 9 hours post infection) presentation of viral peptides originating 
from the infecting virions offers insights that are specifically not possible from peptide binding prediction alone. 
However, the importance of these earlier times should not be overlooked. We calculated the probability that at 
least one peptide would be presented, and found that there was a greater than 50% chance of an efficient Gag 
peptide being presented within 3 hours, explaining the observations of the Gag epitopes KF11 and KK10 within 
3 hours post infection43. The T-cell responses to early peptides could strongly shape the eventual dominating TCR 
clonotypes. In this study, we did not attempt to simulate specific peptide sequences arising from the infecting 
virion, as the required stochastic treatment is computationally cumbersome, instead leaving a more detailed 
analysis to future work.
Whilst we used HIV-1 clade C in this study, our modelling methodology could also be applied to any HIV 
clade for which the full amino acid sequence is available. Naturally, changes in sequence would lead to changes in 
derived peptide sequences, which could both add and remove immunologically relevant peptides. Furthermore, 
changes in viral sequence could have an impact on the rates of transcription and translation of viral proteins, 
however these effects would be difficult to predict. As such, the rates used in our model are not clade-specific. 
Furthermore, as noted above, there is no reason that other viruses could not also be analysed using our approach, 
though the timing of protein accumulation and a quantification of virion composition would be required.
Unfortunately, very little experimental data exists that can quantitatively test the predictions made in this 
model. Quantitative data is difficult to gather experimentally due to the expense involved in these procedures, 
resulting from the large number of peptides which would need to be scanned, and the multiple MHC alleles the 
experiment would have to be repeated on21. Therefore, all of our efforts to compare with experimental obser-
vations are qualitative, but have established that known epitopes are indeed predicted to be presented in high 
abundance. Advances in mass spectrometry have enabled more comprehensive datasets to emerge for other 
viruses, such as LCMV45, which might be used to test the general applicability of this dynamic modelling strat-
egy to predict immune recognition. More high throughput technologies, such as DNA barcoded peptide-MHC 
complexes46, could also help to identify the peptide specificities of T-cell receptors that are relevant for specific 
infections. Knowledge of the hierarchy and timing of the presentation of T-cell epitopes could be helpful in devel-
oping successful T-cell vaccines. Predictive models such as the one presented here are useful for helping to design 
experiments that provide a mechanistic understanding of immune recognition.
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Methods
Prediction of HIV epitopes using bioinformatics tools. We used the MHC class I epitope prediction 
tools available from the IEDB (http://tools.iedb.org/processing/; version 2013-02-22). The tool combines the out-
put of three separate predictions algorithms for proteasomal cleavage, TAP transport and MHC-I-peptide binding 
into a ‘Total Score’24,47. The Total Score is design to be proportional to the cell surface abundance of the peptide 
bound to an MHC I molecule. A Stabilised Matrix Method (SMM)24,48,49 is used in both the proteasomal cleav-
age predictions and TAP-peptide affinity predictions, where the assumption that each amino acid in a sequence 
contributes independently to MHC-I binding, is modified by including pair-wise interactions between the amino 
acids within the peptide. The peptide-MHC binding affinity predictions are provided by the NetMHCpan tool, 
which uses Artificial Neural Networks (ANN)50. The quality of these combined predictions is better than or equal 
to several methods that instead focus on MHC-I peptide binding in isolation24,51, such as BIMAS22. We applied 
the prediction tools to the consensus HIV-1 clade C sequence available at http://www.hiv.lanl.gov/content/index 
for each of the nine HIV-1 proteins. The sequence is used as an input to the tool, and the user can then select 
which HLA allele they want to predict the peptide binding affinities for.
Deterministic simulation of the HIV-1 intracellular kinetics model. We built a dynamical systems 
model of HIV-1 intracellular kinetics by combining three existing models of HIV viral dynamics made up of 
systems of ODEs, Kim & Yin29,52, Reddy & Yin18, and Wang & LuHua30 (Table 1). The model by Kim & Yin29 
describes the translation of full-length (FN) and successive splicing to produced singly-spliced (SN), and 
multiply-spliced (MN) HIV mRNA in the nucleus, the export of these transcripts, the translation of the HIV pro-
teins Rev and Tat and their influence upon mRNA export and transcription rate respectively. Initially, FN is tran-
scribed at the basal cellular transcription rate, TCb; however, once copies of the Tat protein start appearing in the nucleus they can bind to the transactivation response element (TAR), a process which can be modelled according 
to Michaelis-Menten kinetics, using the equilibrium constant of Tat binding with TAR KTat. Full-length mRNA 
can be spliced to produce singly-spliced mRNA, which can then be spliced to produce multiply-spliced mRNA, 
with rate coefficients k ksp
F
sp
S= . Only MN can be independently exported to the cytoplasm, where it can be trans-
lated to produce Rev and Tat, which can then be imported back in to the nucleus. The larger transcripts require 
Rev to bind to the Rev response element (RRE), and once a threshold number of Rev proteins have been bound 
(i Th≥ ), the transcripts can then be exported. The number of Rev proteins bound to a single transcript can range 
from between i1 12≤ ≤ . The binding of Rev to a transcript causes a delay in splicing of factor d. If a full-length 
Figure 10. Simulated HIV mRNA. The model in Table 0 was used to simulate full-length (FC), singly-spliced 
(SC) and multiply-spliced (MC) mRNA copies in the cytoplasm. The full-length cytoplasmic mRNA (FC) reaches 
a steady state level of 3,900 copies, which agrees with the experimentally measured average53.
Description Equation
Gag kinetics f Tr F k Gag k Gag[ ] [ ] [ ]d Gagdt Gag C Gag bud
[ ] = ⋅ − −
GagPol kinetics = ⋅ − −f Tr F k GagPol k GagPol[ ] [ ] [ ]d GagPoldt GagPol C GagPol bud
[ ]
Env kinetics f Tr S k Env k Env[ ] [ ] [ ]d Envdt Env C Env bud
[ ] = ⋅ − −
Vif kinetics f Tr S k Vif k Vif[ ] [ ] [ ]d Vifdt Vif C Vif bud








Table 2. Equations describing intracellular kinetics of HIV proteins Gag, GagPol, Env and Vif. All equations 
and parameters are taken from Wang & LuHua30 or Reddy & Yin18.
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transcript with i bound Rev proteins, FRN
i( ), is spliced with rate coefficient d k(1 ) sp−  this produces singly-spliced 
mRNA with i bound Rev proteins, SRN
i( ). If SRN
i( ) is spliced it produces multiply-spliced mRNA MN  and i free Rev 
proteins. Once the threshold number Th of bound Rev proteins have been reached, the transcripts can be exported 
to the cytoplasm with rate coefficient kexp, where the Rev proteins instantaneously unbind, and are free to shuttle 
back in to the nucleus, with rate coefficient kimp.
The final term on the right-hand side of the equation for FC does not originate from the Kim & Yin model29, 
but instead comes from the Wang & LuHua30 model. This term, − ×2 dVirion
dt
 accounts for the export of full-length 
mRNA to the cell membrane for incorporation in to the budding virion, and ensures the steady-state level of 
full-length mRNA in the cytoplasm remains at the experimental average of 3,90053. The kinetics of Virion are 
described in Equation Set 2 and all parameter values are given in Supplementary Table S1. The resulting cytoplas-
mic mRNA kinetics are shown in Fig. 10.
To model the dynamics of the important structural proteins, Gag, GagPol and Env, we use the model pre-
sented by Reddy and Yin18 for the synthesis and degradation steps (Table 2), although we use the mRNA levels 
produced in the Kim & Yin29 model and the budding rate from Wang & LuHua30. The kinetics of the Vif protein 
are also provided by Wang & LuHua30. All parameters used here are taken from Wang & LuHua30 or Reddy and 
Yin18. Full-length mRNA encodes for the important structural proteins Gag and GagPol, with are translated with 
rate coefficients ⋅f TrGag  and ⋅f TrGagPol  respectively, where fProt are the translation fractions and Tr is the trans-
lation rate. Each protein degrades with rate coefficient kProt and is exported to the cell membrane for budding with 
rate constant kbud.
For the remaining HIV-1 proteins, Vpr, Vpu and Nef, not included in any of the existing three models, we used the 
general equation for the protein kinetics in the cytoplasm, i.e. d dt f Tr mRNA k k[Prot ]/ [ ] [Prot ] [Prot ]j j j j bud j= ⋅ − − , 
using experimentally measured values for kj when available, and using the same value of kbud as given in Wang & 
LuHua30. The synthesis fractions fj were set so that the amount of protein being incorporated in to one virion via the 
budding term was equal to the experimentally determined concentration of the protein found in a HIV virion. All 
three models use parameters taken from the literature and compare their results with experimental data where avail-
able. Combining these three models, along with experimental measurements of missing rates such as protein 
half-lives, produces an almost complete model of all HIV intracellular kinetics, in terms of viral protein dynamics. 
This model can be updated as more experimental data becomes available and the parameters values can be refined.
Quantifying peptide-dependent rates. To predict the differences in the cell surface presentation of HIV 
peptides by controlling and non-controlling alleles using this model, we required methods for quantifying the 
rates of peptide unbinding of MHC-I, proteasomal cleavage and peptide degradation in the cytoplasm. We 
applied the following methods to the consensus sequences of HIV clade C from the Los Alamos National 
Laboratory (LANL) HIV database to obtain relative values for peptide unbinding, proteasomal cleavage and 
peptide degradation. We decided to ignore the impact of peptide-dependent TAP binding in this study, as the 
sensitivity analysis suggested it to have only a minor role in shaping cell surface presentation on MHC-I mole-
cules (Fig. 5). We required that the IEDB predicted peptide-MHC affinity values be comparable between alleles. 
Therefore, we rescaled the IC50 affinity values according to the method in ref.54 and used in similar studies to 
this28,55. We acquired the predicted IC50 values for the peptides from the Mycobacterium Tuberculosis proteome 
to obtain a dataset of over 500,000 partially overlapping natural peptides. For each allele studied here we obtained 
three separate datasets for the 9mers, 10mers and 11mers. We then combined the three datasets and took the top 
1% of binders as the IC50 threshold for binding peptides for each allele. The rescaling method described in ref.54 
normalises each IC50 by dividing by the threshold IC50 value. However, for our purposes we require a rescaled IC50 
value that is still in units of nM. Therefore, we arbitrarily chose one allele as the reference allele and then rescaled the 
predicted IC50 values relative to that allele. The reference allele was chosen to be HLA-B*58:01, and its threshold 
affinity as determined using the method described above is denoted IB58. When rescaling the predicted IC50 values 
for say HLA-B*57:01, we would multiply the IC50 value by the ratio of the threshold of B*58:01 to the threshold of 
B*57:01. Therefore, for allele a, the rescaled IC50 values are calculated as follows: =IC IC I I50 50aR a B a58 , where IC50aR 
is the rescaled IC50 of allele a, IC50a is the original IC50 and Ia is the rescale threshold of allele a.
Peptide unbinding from MHC-I. While there exist prediction methods for peptide-MHC stability directly, such as 
NetMHCstab and NetMHCstabpan, none have been calibrated to cover the HLA alleles that are of interest in this 
study. Therefore, we based our quantification of peptide off-rate on the more common affinity-based methods that 
are suggested in the IEDB MHC-I processing tool, but note that this will likely induce some degree of inaccuracy6. 
We first assumed that the predicted IC50 value for each peptide binding to an MHC allele is approximately equal to 
the dissociation constant56–59, Kd, where K u b/d P=  where u and bP are the peptide MHC unbinding and binding 
rates respectively. We then assumed that the binding rate is constant for each peptide, as experimental evidence 
shows that there is much less variation in HIV peptide binding rates than in the peptide off-rates60, and used the 
value 219 M−1 s−1 measured in ref.61. This enabled us to estimate the unbinding rate of each peptide as u K bd P= .
Proteasomal cleavage. The IEDB tool outputs a cleavage score for each peptide that is proportional to the logarithm of 
the amount of peptide generated from the cleavage of the peptides C-terminal. We converted this to a relative cleavage 
probability for each peptide sequence. First, we established a range in which these relative probabilities should lie. The 
well known peptide SIINFEKL, or an N-terminally extended version of it, was measured to be produced via degrada-
tion of the OVA protein 6–8% of the time it degrades62. The range of the IEDB predicted relative abundances were in the 
range [1, 80]. Therefore, we scaled these values down by a factor 1000, producing cleavage scores in the range [0, 0.08], 
consistent with SIINFEKL being produced from OVA degradation with high probability.
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The peptide filtering model for MHC-I antigen presentation. The peptide filtering model is a 
dynamical systems description of peptide-MHC binding and presentation at the cell surface33. The equations are 
reproduced in Supplementary Equation Set S3. Here, we provide a short description of how the underlying bio-
chemistry is modelled. A peptide Pi is supplied to the ER with supply rate coefficient gi, where it can either be 
degraded with rate constant dP or bind to an MHC molecule M with rate bP, or an MHC-tapasin complex with a 
higher rate cP. Tapasin is a chaperone molecule that binds to the peptide loading complex and ensures that only 
high affinity peptides are presented on the cell surface. Tapasin and MHC are supplied to the ER with rate coeffi-
cients gT  and gM  and degrade with rate coefficients dT  and dM  respectively. The peptide-MHC complex MPi 
unbinds with the peptide sequence-dependent rate constant ui, whilst the peptide unbinds the 
peptide-MHC-tapasin complex with a faster rate coefficient q ui⋅  (q > 1). MHC-tapasin complexes dissociate 
with rate uT, whereas in the presence of the peptide, tapasin unbinds the peptide-MHC-tapasin complex with an 
increased unbinding rate coefficient u vT ⋅ . Finally, a peptide-MHC complex can egress to the cell surface with 
rate coefficient e, where the peptide again unbinds from MHC-I with rate ui.
In all, there are five peptide-dependent equations. Therefore, if the IEDB prediction tool predicts n peptides 
with an IC50 less than 500 nM, then there will be approximately n5  equations in the system. In some cases the 
IEDB tool predicts that hundreds of peptides from the entire HIV genome will bind to the HLA allele in question, 
resulting in a very large system which must be solved numerically, especially in the case of the deterministic intra-
cellular kinetics model. As the resulting model has stiff kinetics, we used Matlab’s ode15s integrator. We provide 
the Jacobian matrix for the system as a sparse matrix to prevent the need for the solver to approximate the 
Jacobian numerically, which in this case would create an unnecessary memory burden.
Self-peptides. Viral peptides compete not only with each other but also with self-peptides for MHCI binding and 
presentation. Self-peptides originate from native host proteins and can also be presented on the cell surface, however 
they should not initiate a T-cell response due to negative selection of self-reactive T-cells. Just like the viral peptides, 
these self-peptides will have a range of proteasomal cleavage probabilities, ER supply rates and MHCI binding rates. 
However, there are too many self-peptides to represent explicitly in the model. Therefore, to model the impact of 
the competition of these self-peptides we represented the self-peptides by four additional peptides in the simulation. 
These four peptides were given a range of unbinding and supply rates (see Table S5 for parameters). Each different 
MHC allele will only bind a small subsection of the ER peptidome with high affinity, and so the self-peptides with a 
medium unbinding rate (1 × 10−3 s−1) were assumed to make up the majority of the peptides being transported in to 
the ER and were allocated a large fraction of the total supply rate. TAP binds between 2–5 peptides per second, and 
there are approximately 10,000 copies of TAP per cell20. We assigned the total rate of TAP transport of self-peptides 
to be the lower end of this range (20,000 peptides per second) to maximise viral peptide presentation. The kinetics of 
the self-peptides are given by are identical to those described for peptides in Equation S3.
Sensitivity analysis. We performed a sensitivity analysis on a small subset of the model parameters for the 
deterministic system of HIV intracellular kinetics, using the SUNDIALS CVODES63 forward sensitivity analysis 
(FSA) in MATLAB, with the aim of comparing the importance of different parameters which are known to influ-
ence cell surface abundance: peptide-MHC binding rate bP, peptide-MHCI-tapasin binding rate cP, 
peptide-MHCI unbinding rate ui, protein translation (where here we used the translation fractions of each protein 
fj), protein degradation rate kj, proteasomal cleavage probability pci and peptide ER supply rate gi.
The sensitivity of a system of nonlinear first order ODEs θ=x f t x( , , )  with respect to the kth parameter kθ  is 










































The CVODES FSA approximates si by a centred difference quotient. Both the sensitivities and ODE systems 

































Table 3. Chemical reaction network model of peptide filtering. The reactions are extended from33 to include 
the degradation of protein j, and proteasomal cleavage and ER translocation from the cytosol of peptide i. The 
superscripts denote the compartment containing the molecules (cyt - cytoplasm; cs - cell surface), with no 
superscript denoting ER. The superscript is omitted from Protj, which is always in the cytoplasm.
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output of our combined model by considering =x MP[ ]i i cs. To normalize each time-dependent sensitivity coeffi-






 by θ MP t/[ ] ( )k i cs0 , as described in ref.
37.
Virion model. The deterministic model of HIV intracellular replication describes the concentration of each 
species as a continuous variable, and so in fact describes the average of the population. The assumption that reac-
tions occur at a constant rate is value when considering large numbers of molecules of each interacting species, as 
is being simulated in the large combined model described above. However, when simulating very small popula-
tions of molecules however, the reacting molecules will not come in to contact at a constant rate and a determin-
istic model that uses constant reaction rates would not describe this system very well as one would expect to see a 
large variation from the average behaviour of a larger system. The discrete stochastic formulation considers the 
exact number of molecules present in the system at that time and the probability of each possible reaction occur-
ring within a certain time interval. This assumes that the probability of the reaction +A B C
k
 firing in time 
interval t t dt[ , )+  is exponentially distributed with mean A t B t dt( ) ( ) .
For simulating cell surface presentation of virion-derived peptides, we used a stochastic model equivalent to 
the equations of Table S3, which uses elementary chemical reactions to describes the copy numbers of each 
molecular species as discrete variables. The complete set of reactions is given in Table 3. The peptides are pro-
duced as described in equation 1, and connected up to the MHC peptide filtering model using the supply term 
g P[ ]i i cyt as before.
To perform the stochastic simulations, we used the Visual GEC software http://research.microsoft.com/gec, 
which uses Gillespie’s stochastic simulation algorithm64 (SSA) to simulate chemical reaction networks. As the 
algorithm is stochastic, each trajectory produced can only be considered as one sample from a distribution of 
samples. Therefore, we always used 300 independent trajectories, and computed statistics based on these such as 
the mean copy number, or the probability of there being at least one copy.
Calculating overall presentation using conditional probability. Suppose we denote by S t( ) the sur-
face presentation at time t. Conditional probability enables us to compute the total probability of presentation by 
separating out the influence of the number of infecting virions N. Accordingly,
∑≥ = ≥ | = . =
=
∞
P S t P S t N i P N i( ( ) 1) ( ( ) 1 ) ( )
(3)i 0
By assuming that N is Poisson distributed with mean 1, we can easily combine simulations of the combined 
model for different numbers of virions. In the calculations of Fig. 9D, we included simulations up to 5 virions, 
which covers 99.9% of the probability mass for a Poisson with mean 1.
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